Conagra is in a sustained downtrend, with the stock price falling 29.0% over the past year compared to a 20.6% gain in the S&P 500. The current price of $13.83 sits at just 68% of its 52-week range (low $12.53, high $20.32), indicating the stock is trading near the bottom of its range. This positioning near the 52-week low suggests the market is pricing in significant fundamental deterioration, though it could also represent a deep value opportunity if the company's turnaround efforts succeed. Short-term momentum shows a mixed picture: the 1-month price change is +3.7%, while the 3-month change is -8.9%. The positive 1-month return contrasts with the longer-term downtrend, potentially signaling a short-term bounce or mean reversion attempt. However, the relative strength versus the S&P 500 remains deeply negative at -20.0% over 3 months and -49.7% over 1 year, confirming persistent underperformance. The stock's beta is -0.047, indicating virtually no correlation with the broader market—an unusual characteristic that suggests company-specific factors are driving price action. Key support lies at the 52-week low of $12.53; a break below that level would signal further downside and likely test multi-year lows. Resistance is at the 52-week high of $20.32, and a move above that would require a fundamental catalyst. The stock's low beta implies that it offers no diversification benefit and is driven by idiosyncratic risks, making position sizing particularly important.

Revenue is in decline: the most recent quarter (Q2 fiscal 2026, ended November 23, 2025) reported revenue of $2.979 billion, down 6.8% year-over-year from $3.195 billion in the prior-year quarter. This marks a deceleration from earlier periods—Q1 fiscal 2026 revenue was $2.633 billion (down 5.8% YoY), and the prior fiscal year's Q4 revenue was $2.782 billion. The revenue decline is broad-based, with the Grocery & Snacks segment at $1.209 billion and Refrigerated & Frozen at $1.251 billion, both facing volume and pricing pressures. The negative growth trajectory is a major concern for the investment case, as it suggests market share losses and weak consumer demand for Conagra's brands. Profitability has deteriorated sharply: the company reported a net loss of $663.6 million in Q2 fiscal 2026, compared to net income of $284.5 million in the same quarter last year. Gross margin contracted to 23.4% from 26.5% a year ago, reflecting cost inflation and pricing challenges. The operating margin was 12.5%, down from 12.6% in the prior-year quarter, but the net margin turned deeply negative at -22.3% due to a $1.027 billion impairment charge. On a trailing twelve-month basis, net income was negative, but the company has historically been profitable; the key question is whether margins can recover as input costs stabilize. The balance sheet shows elevated leverage: debt-to-equity is 0.90, and the current ratio is a low 0.71, indicating liquidity risk. Free cash flow over the trailing twelve months was $876.4 million, providing some cushion, but the company's ability to service its debt is a concern given the negative net income. Return on equity (ROE) of 12.9% is decent but has been volatile. The high dividend payout ratio of 58.1% and a dividend yield of 6.25% suggest the dividend is at risk if earnings do not recover.